

Population-level Estimation #1: Hydroxychloroquine

Dani Prieto-Alhambra University of Oxford



BACKGROUND What have we achieved?



1. What is the safety profile of hydroxychloroquine?

2. What is its potential anti-viral efficacy?



METHODS

DESIGN

- 1. Comparative cohort HCQ (t) vs SSZ (o) in RA patients
- 2. SCCS (regardless of indication)

PARTICIPANTS

- 1. RA diagnosis + new use of HCQ or SSZ
- 2. HCQ use (on/off) + outcome of interest ("case")



METHODS (2)

OUTCOMES

- 1. Serious adverse events, including: arrhythmia, cv disease, vte, liver failure, kidney failure, GI bleeds, mortality
- 2. Flu/viral infections, hospitalized pneumonia (not in SCCS)

ANALYSES

- 1. PS stratification + negative control outcome calibration
 - On treatment and ITT (up to 5y)
- 2. Age and season-adjusted SCCS



RESULTS (VTE) *Power*

DATA SOURCE	N HCQ	N SSZ	T events HCQ	C events SSZ
CCAE	66,162	23,319	641	159
CPRD	9,134	11,401	131	176
IQVIA-DE	3,898	5,052	34	47
OPTUM	51,288	17,464	946	209
TOTAL	130,482	57,236	1,752	591





RESULTS (VTE) Diagnostics (CCAE)

- ✓ PS overlap
- ✓ Covariate balance
- ✓ Negative control outcomes





RESULTS (3) *Risk estimates*

$\leftarrow \ \rightarrow $	C	data.ohdsi.org/Covid19EstimationHydroxychloroquine/						Q 🕁	0	🔷 🥃	:		
Apps	•	EUADRSharePoint	EU-ADR Home	t. EMIF	S EMIF Catalogue	AppsSIDIAP	S Revalidation	AEMPS-CIMA	S NHS_e_Learning	S Variables SIDIAP	0	Sampsize	>>

OHDSI COVID-19 Studyathon: Hydroxychloroquine population-level effect estimation

About Explore results

[OHDSI Cov19] New users of Hydroxychloroquine with prior rheumatoid arthritis

Comparator

Target

[OHDSI Cov19] New users of sulfasazine with prior rheumatoid arthritis

Outcome

[LEGEND HTN] Venous thromboembolic (pulmonary embolism and deep vein thrombosis) events

Data source

CCAE

CPRD

IQVIA_GERMANY

OptumDOD

Analysis	Data source	HR 🕴	LB 💠	UB 🛊	P 💠	Cal.HR	Cal.LB	Cal.UB	
No prior outcome in last 30d, 5 PS strata, TAR on-treatment+14d	CCAE	0.99	0.82	1.20	0.92	1.00	0.74	1.35	
No prior outcome in last 30d, 5 PS strata, TAR on-treatment+14d	CPRD	1.06	0.81	1.38	0.66	1.01	0.52	1.98	
No prior outcome in last 30d, 5 PS strata, TAR on-treatment+14d	IQVIA_GERMANY	0.98	0.58	1.63	0.94	0.72	0.42	1.23	
No prior outcome in last 30d, 5 PS strata, TAR on-treatment+14d	OptumDOD	1.04	0.89	1.22	0.64	1.06	0.84	1.32	
No prior outcome in last 30d, 5 PS strata, TAR intent-to-treat 5yr	CCAE	0.97	0.87	1.07	0.51	0.98	0.88	1.10	
No prior outcome in last 30d, 5 PS strata, TAR intent-to-treat 5yr	CPRD	0.99	0.83	1.19	0.94	1.01	0.83	1.23	
No prior outcome in last 30d, 5 PS strata, TAR intent-to-treat 5yr	IQVIA_GERMANY	0.86	0.65	1.14	0.30	0.76	0.57	1.02	
No prior outcome in last 30d, 5 PS strata, TAR intent-to-treat 5yr	OptumDOD	0.95	0.87	1.04	0.24	0.97	0.88	1.07	

Showing 1 to 8 of 8 entries

Previous



RESULTS (3) *Risk estimates*

Analysis	🔶 Data source	🔶 HR 🔶	LB 🔶	UB 🕴	P 🔶	Cal.HR	🔶 Cal.LB	Cal.UB	🔶 Cal.P 👌
No prior outcome in last 30d, 5 PS strata, TAR on-treatment+14d	CCAE	0.99	0.82	1.20	0.92	1.00	0.74	1.35	0.88
No prior outcome in last 30d, 5 PS strata, TAR on-treatment+14d	CPRD	1.06	0.81	1.38	0.66	1.01	0.52	1.98	0.83
No prior outcome in last 30d, 5 PS strata, TAR on-treatment+14d	IQVIA_GERMANY	0.98	0.58	1.63	0.94	0.72	0.42	1.23	0.28
No prior outcome in last 30d, 5 PS strata, TAR on-treatment+14d	OptumDOD	1.04	0.89	1.22	0.64	1.06	0.84	1.32	0.69
No prior outcome in last 30d, 5 PS strata, TAR intent-to-treat 5yr	CCAE	0.97	0.87	1.07	0.51	0.98	0.88	1.10	0.77
No prior outcome in last 30d, 5 PS strata, TAR intent-to-treat 5yr	CPRD	0.99	0.83	1.19	0.94	1.01	0.83	1.23	0.73
No prior outcome in last 30d, 5 PS strata, TAR intent-to-treat 5yr	IQVIA_GERMANY	0.86	0.65	1.14	0.30	0.76	0.57	1.02	0.09
No prior outcome in last 30d, 5 PS strata, TAR intent-to-treat 5yr	OptumDOD	0.95	0.87	1.04	0.24	0.97	0.88	1.07	0.56



DISCUSSION

COMPLETED

✓ The biggest study to date on the safety of HCQ
✓ Reassuringly, no consistent signals found

WORK IN PROGRESS

- Running across the whole network (where possible)
- SCCS

OUTSTANDING

• Anti-viral efficacy (new user design in COVID19 infectees)